

7:30	S-20 Are anti-inflammatory treatments really useful in depression?	S-21 OCD: Enigma wrapped in a riddle	S-22 Towards digital-based care of schizophrenia: Where are we heading?	S-23 COVID-19 and mental health: What do we know?	S-24 The microbiota-gut-brain axis in psychiatric disorders: Gene-environment interactions and therapeutic targets	S-25 Treatment and outcome of different clinical facets of Bipolar disorder
8:00						
8:30						
9:00						
9:30	D-02 The Amyloid Hypothesis is the key for a cure for Alzheimer's Disease	S-26 Purinergic mechanisms in psychiatric disorders	WS-01 Immune system and suicidal behaviour: What do we know?	S-27 Psychedelics – a way out of the box?	S-28 Pharmacogenomics and personalized medicine for antipsychotic and antidepressant medications: are we there yet?	ES-02 Understanding and designing genetic studies
10:00						
10:30						
11:00						
11:30	Satellite Symposia					
12:00						
12:30						
13:00						
13:30	TFS-03 Tools for optimizing pharmacotherapy in psychiatry: Focus on antipsychotics	TFS-04 Psychopathology in times of precision psychiatry	S-29 Nature and nurture in suicidal behaviour: latest updates	S-30 Update on the WFSBP guidelines for the Pharmacological Treatment of Eating Disorders	S-31 Can translational research enhance the efficacy of rTMS in MDD?	ES-03 Machine learning approaches for biological psychiatry
14:00						
14:30						
15:00						
15:30	Plenary Lecture					
16:00	PL-02 Interpersonal psychotherapy – A global reach (Myrna Weissman, USA)					
16:30						
17:00	S-32 ENIGMA and the PGC: Large-scale studies of psychiatric genetics and brain imaging	TFS-05 Identification of neuro-progressive profiles and course in recurrent affective disorders Part 2	WS-02 Next-step treatment considerations in patients with treatment-resistant depression that respond to low-dose intravenous ketamine	S-33 Canadian Network for Mood and Anxiety treatments (CANMAT): update of novel treatments and approaches for Bipolar Disorder	S-34 Precision psychiatry: The case of treatment resistant schizophrenia	S-35 Clearing the smoke: Cannabis, Mood Disorders and Schizophrenia. A CANMAT Symposium
17:30						
18:00						
18:30						
19:00	Satellite Symposia					
19:30						
20:00						
20:30	Virtual Posters accessible all day					
21:00						
21:00–23:00 ▶ WFSBP General Assembly						

All sessions run in Central European Summer Time (CEST).